A New Crystal Engineering Technique for Dissolution Enhancement of Poorly Soluble Drugs Combining Quasi-emulsion and Crystallo-co Agglomeration Methods
Authors
Abstract:
A target of best dissolution improvement of poorly soluble drugs is a necessity for the success of formulation in industry. The present work describes the preparation, optimization, and evaluation of a new spherical agglomeration technique for glimepiride as a model of poorly soluble drugs. It involved the emulsification of a drug solution containing a dispersed carrier that tailors the crystal habit of the drug to a perfect spherical geometry, in a poor solvent containing a hydrophilic polymer which imparts sphericity and strength to the formed agglomerates. The FTIR peaks of optimized product did not show any sign of chemical interaction between the drug and adsorbed carrier. The DSC and X ray diffractogram showed a peak characteristic of spherical agglomerates with much less intensity than that of glimepiride. The dissolution t1/2 of the drug slightly decreasedfrom 381 min to 334 min in plain agglomerates. Introducing polymers in the aqueous phase of emulsion led to an improvement in the dissolution, reflected in t1/2 ranging from 118 to 231 min. Agglomerates prepared with Starlac/PVP demonstrated the most optimum physicochemical characteristics being spherical, with the best flowability and packability parameters. The t1/2 was as short as 19 min. The new carrier/polymer system offered a synergistic combination that highly contributed in dissolution enhancement of glimepiride. The spheronization and amorphisation offered by the new technique could account for such improvement.
similar resources
Dissolution Enhancement of Poorly Soluble Drugs by Using Complexation Technique – A Review
Orally administered drugs completely absorb only when they show fair solubility in gastric medium and shows good bioavailability. The solubility properties of drug play an important role in the process of formulation developments. Problem of solubility can be solved by different approaches. Each approach suffers with some limitations and advantages. Among all, complexation techinque has been em...
full textDissolution Testing for Poorly Soluble Drugs: A Continuing Perspective
The development of a meaningful dissolution procedure for drug products with limited water solubility has been a challenge to both the pharmaceutical industry and the agencies that regulate them. These challenges include developing and validating the test methods, ensuring that methods are appropriately discriminatory, and addressing the potential for an in vivo–in vitro correlation (IVIVC). Di...
full textStudies on dissolution enhancement of prednisolone, a poorly water-soluble drug by solid dispersion technique.
INTRODUCTION Prednisolone is a class II substance according to the Biopharmaceutics Classification System. It is a poorly water soluble agent. The aim of the present study was to improve dissolution rate of a poorly water-soluble drug, prednisolone, by a solid dispersion technique. METHODS Solid dispersion of prednisolone was prepared with PEG 6000 or different carbohydrates such as lactose a...
full textLiquisolid Compacts: An Effective Approach towards Enhancement of Dissolution Rate of Poorly Soluble Drugs
Department of pharmaceutics, Hindu College of Pharmacy, Guntur, Andhra Pradesh, India. ______________________________________________________________________ ABSTRACT Poorly water-soluble drugs involve many difficulties in the development of pharmaceutical dosage forms for oral delivery systems due to their low bioavailability. Therapeutic effectiveness of a drug depends upon the bioavailabilit...
full textSolubility Enhancement of Poorly Water Soluble Drugs: a Review
Among all newly discovered chemical entities about 40% drugs are lipophillic and fail to reach market due to their poor water solubility. Drug with poor water solubility cause slow dissolution rates, generally show erratic and incomplete absorption leading to low bioavailability when administered orally. Aqueous solubility of any therapeutically active substance is a key property, as it governs...
full textMy Resources
Journal title
volume 19 issue 2
pages 219- 235
publication date 2020-06-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023